South Dakota Investment Council Buys Shares of 7,300 NeoGenomics, Inc. (NEO)

South Dakota Investment Council bought a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) in the first quarter, HoldingsChannel reports. The institutional investor bought 7,300 shares of the medical research company’s stock, valued at approximately $149,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc boosted its position in shares of NeoGenomics by 24.0% during the 3rd quarter. Vanguard Group Inc now owns 3,839,641 shares of the medical research company’s stock valued at $58,939,000 after acquiring an additional 743,245 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of NeoGenomics by 26.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 882,244 shares of the medical research company’s stock valued at $13,543,000 after acquiring an additional 182,172 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of NeoGenomics by 29.0% during the 4th quarter. Los Angeles Capital Management & Equity Research Inc. now owns 64,134 shares of the medical research company’s stock valued at $809,000 after acquiring an additional 14,405 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in NeoGenomics by 28.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 965,790 shares of the medical research company’s stock valued at $14,825,000 after buying an additional 212,937 shares during the period. Finally, Morgan Stanley raised its holdings in NeoGenomics by 716.1% during the 3rd quarter. Morgan Stanley now owns 1,056,917 shares of the medical research company’s stock valued at $16,225,000 after buying an additional 927,403 shares during the period. Hedge funds and other institutional investors own 76.36% of the company’s stock.

Shares of NEO stock opened at $23.57 on Friday. NeoGenomics, Inc. has a 1-year low of $11.05 and a 1-year high of $23.85. The stock has a market cap of $2.20 billion, a P/E ratio of 181.31 and a beta of 0.91. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.46 and a current ratio of 1.59.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, April 30th. The medical research company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. NeoGenomics had a positive return on equity of 3.07% and a negative net margin of 0.14%. The company had revenue of $95.60 million for the quarter, compared to the consensus estimate of $89.71 million. During the same quarter last year, the company earned $0.04 earnings per share. The firm’s revenue for the quarter was up 50.8% compared to the same quarter last year. On average, equities analysts anticipate that NeoGenomics, Inc. will post 0.19 earnings per share for the current fiscal year.

Several analysts recently weighed in on NEO shares. BidaskClub upgraded NeoGenomics from a “hold” rating to a “buy” rating in a report on Tuesday, January 29th. Zacks Investment Research lowered NeoGenomics from a “buy” rating to a “hold” rating in a report on Saturday, March 2nd. CIBC upgraded NeoGenomics from a “neutral” rating to an “outperform” rating and decreased their price target for the company from $18.00 to $15.00 in a report on Tuesday, March 12th. Finally, Needham & Company LLC increased their price target on NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a report on Friday, March 29th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $20.00.

In other NeoGenomics news, insider William Bonello sold 7,200 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $23.53, for a total value of $169,416.00. Following the completion of the sale, the insider now owns 13,935 shares of the company’s stock, valued at $327,890.55. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Jennifer Balliet sold 30,000 shares of the firm’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $19.57, for a total value of $587,100.00. Following the completion of the sale, the vice president now directly owns 40,000 shares of the company’s stock, valued at approximately $782,800. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 602,400 shares of company stock worth $12,693,858. 12.20% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “South Dakota Investment Council Buys Shares of 7,300 NeoGenomics, Inc. (NEO)” was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.baseballdailydigest.com/news/2019/05/17/south-dakota-investment-council-buys-shares-of-7300-neogenomics-inc-neo.html.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Recommended Story: What are retained earnings?

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.